NCT00051311 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Apheresis: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
- id
- FG000
- title
- Donor
- description
- Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells. Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD). Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
- id
- FG001
- title
- Recipient
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Starting new study
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Pt. to pursue treatment for progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 8
- group Id
- FG001
- num Subjects
- 8
- type
- Death of recipient
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- type
- Recipient taken off study
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 31
- group Id
- FG001
- num Subjects
- 31
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 19
- group Id
- FG001
- num Subjects
- 17
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 14
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Apheresis: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
- id
- FG000
- title
- Donor
- description
- Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells. Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD). Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
- id
- FG001
- title
- Recipient
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Starting new study
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Pt. to pursue treatment for progressive disease
- reasons
- group Id
- FG000
- num Subjects
- 8
- group Id
- FG001
- num Subjects
- 8
- type
- Death of recipient
- reasons
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- type
- Recipient taken off study
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 31
- group Id
- FG001
- num Subjects
- 31
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 19
- group Id
- FG001
- num Subjects
- 17
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 14
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle